Rapid Micro Biosystems to Exhibit at the 2024 PDA Annual Meeting from March 25 - 27, 2024
2024年3月20日 - 5:30AM
Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an
innovative life sciences technology company providing mission
critical automation solutions to facilitate the efficient
manufacturing and fast, safe release of healthcare products, today
announced that it will exhibit at the 2024 Parenteral Drug
Association (“PDA”) Annual Meeting from March 25 – 27, 2024 in Long
Beach, CA.
This year’s PDA Annual Meeting is at the core of the inaugural
PDA Week that features many events including training, roundtables,
presentations and tours that address the opportunities and
challenges most relevant to the future of pharmaceutical
microbiology. Attendees will include global microbiology and QA/QC
process professionals, regulators, academia and pharmaceutical
industry consultants.
Rapid Micro’s booth, #435, will showcase the benefits of
automating microbial quality control (“MQC”) testing using the
Growth Direct® System software and technology for rapid incubation,
detection and enumeration.
Additionally, following the recent announcement of the upcoming
availability of a Rapid Sterility application for the Growth
Direct®, the Company will be hosting a technical presentation
entitled “Rapid Sterility Testing as the Critical and Final Result
for Product Release,” on March 26, 2024, at 9:45 a.m. PT in Exhibit
Hall A.
The presentation will include information on the new Growth
Direct® Rapid Sterility Application, which is the only fully
automated, non-destructive, growth-based platform for sterility
testing. This innovative solution is designed to deliver time to
organism detection (“TTD”) in as little as 12 hours and final
time-to-result (“TTR”) in as little as one to three days,
representing a significant improvement over widely used test
methods, which generally require a 14-day endpoint incubation.
These results also support compelling differentiation when compared
to current rapid sterility products.
For additional information, please refer to the Rapid Micro
Biosystems website, the Growth Direct Rapid Sterility microsite and
the PDA conference website, 2024 PDA Annual Meeting.
About Rapid Micro Biosystems
Rapid Micro Biosystems is an innovative life sciences technology
company providing mission critical automation solutions to
facilitate the efficient manufacturing and fast, safe release of
healthcare products such as biologics, vaccines, cell and gene
therapies, and sterile injectables. The Company’s flagship Growth
Direct System automates and modernizes the antiquated, manual MQC
testing workflows used in the largest and most complex
pharmaceutical manufacturing operations across the globe. The
Growth Direct System brings the quality control lab to the
manufacturing floor, unlocking the power of MQC automation to
deliver the faster results, greater accuracy, increased operational
efficiency, better compliance with data integrity regulations, and
quicker decision making that customers rely on to ensure safe and
consistent supply of important healthcare products. The Company is
headquartered and has U.S. manufacturing in Lowell, Massachusetts,
with global locations in Lexington, Massachusetts, Switzerland,
Germany, and the Netherlands.
For more information, please
visit www.rapidmicrobio.com or follow the Company on X
(formerly known as Twitter) at @rapidmicrobio or
on LinkedIn.
Forward-Looking Statements
This press release includes forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. All statements contained in this press release that do not
relate to matters of historical fact should be considered
forward-looking statements, including, but not limited to,
statements regarding the commercial launch of the Growth Direct®
Rapid Sterility application and its intended benefits and
advantages. In some cases, you can identify forward-looking
statements by terminology such as “outlook,” “aim,” “anticipate,”
“assume,” “believe,” “contemplate,” “continue,” “could,” “due,”
“estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,”
“predict,” “potential,” “positioned,” “seek,” “should,” “target,”
“will,” “would” and other similar expressions that are predictions
of or indicate future events and future trends, or the negative of
these terms or other comparable terminology, although not all
forward-looking statements contain these words. Forward-looking
statements involve known and unknown risks, uncertainties and
assumptions which may cause actual results to differ materially
from any results expressed or implied by any forward-looking
statement, including, but not limited to, the risks and
uncertainties associated with a commercial product launch, and the
other important factors outlined under the caption “Risk Factors”
in the Company’s Annual Report on Form 10-K filed with the
Securities and Exchange Commission (“SEC”) on March 1, 2024, as
such factors may be updated from time to time in its other filings
with the SEC. Although the Company believes that the expectations
reflected in its forward-looking statements are reasonable, it
cannot guarantee future results. The Company has no obligation, and
does not undertake any obligation, to update or revise any
forward-looking statement made in this press release to reflect
changes since the date of this press release, except as may be
required by law.
Investor Contact:
Michael Beaulieu, CFA
Vice President, Investor Relations and Corporate Communications
investors@rapidmicrobio.com
Media Contact:
media@rapidmicrobio.com
Rapid Micro Biosystems (NASDAQ:RPID)
過去 株価チャート
から 1 2025 まで 2 2025
Rapid Micro Biosystems (NASDAQ:RPID)
過去 株価チャート
から 2 2024 まで 2 2025